SEARCH:   Advanced

Blood, 15 January 2008, Vol. 111, No. 2, pp. 558-565. Prepublished online as a Blood First Edition Paper on October 25, 2007; DOI 10.1182/blood-2007-06-095331. This Article Full Text Full Text (PDF) Supplemental Appendix Erratum (v111,p5761) All Versions of this Article: blood-2007-06-095331v1 111/2/558    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hoster, E. Articles by Unterhalt, M. Search for Related Content PubMed PubMed Citation Articles by Hoster, E. Articles by Unterhalt, M. Related Collections Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Eva Hoster1,2, Martin Dreyling1, Wolfram Klapper3, Christian Gisselbrecht4, Achiel van Hoof5, Hanneke C. Kluin-Nelemans6, Michael Pfreundschuh7, Marcel Reiser8, Bernd Metzner9, Hermann Einsele10, Norma Peter11, Wolfram Jung12, Bernhard Wörmann13, Wolf-Dieter Ludwig14, Ulrich Dührsen15, Hartmut Eimermacher16, Hannes Wandt17, Joerg Hasford2, Wolfgang Hiddemann1, Michael Unterhalt1, for the German Low Grade Lymphoma Study Group (GLSG) and the European Mantle Cell Lymphoma Network 1 Department of Internal Medicine III, and 2 Department of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany; 3 Institute of Pathology, Lymph Node Registry, University of Kiel, Kiel, Germany; 4 Department of Hematology, Hôpital Saint Louis, Paris, France; 5 Department of Hematology, Akademisch Ziekenhuis St-Jan, Bruges, Belgium; 6 Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 7 Department of Internal Medicine I, Saarland University Medical School, Homburg, Germany; 8 Department of Internal Medicine I, University of Cologne, Cologne, Germany; 9 Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany; 10 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany; 11 Department of Hematology/Oncology, Carl-Thiem Hospital, Cottbus, Germany; 12 Department of Hematology and Oncology, University of Göttingen, Göttingen, Germany; 13 Städtisches Klinikum Braunschweig, Braunschweig, Germany; 14 Department of Hematology and Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany; 15 Department of Hematology, University Hospital Essen, Essen, Germany; 16 Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany; and 17 Medical Department 5, Klinikum Nürmberg Nord, Nuremberg, Germany There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for diffuse large cell and follicular lymphoma patients, respectively. Using data of 455 advanced stage MCL patients treated within 3 clinical trials, we examined the prognostic relevance of IPI and FLIPI and derived a new prognostic index (MCL international prognostic index, MIPI) of overall survival (OS). Statistical methods included Kaplan-Meier estimates and the log-rank test for evaluating IPI and FLIPI and multiple Cox regression for developing the MIPI. IPI and FLIPI showed poor separation of survival curves. According to the MIPI, patients were classified into low risk (44% of patients, median OS not reached), intermediate risk (35%, 51 months), and high risk groups (21%, 29 months), based on the 4 independent prognostic factors: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. Cell proliferation (Ki-67) was exploratively analyzed as an important biologic marker and showed strong additional prognostic relevance. The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD Jatin J. Shah, Luis Fayad, and Jorge Romaguera Blood 2008 112: 2583. [Full Text] [PDF] This article has been cited by other articles: M. Wang, Y. Oki, B. Pro, J. E. Romaguera, M. A. Rodriguez, F. Samaniego, P. McLaughlin, F. Hagemeister, S. Neelapu, A. Copeland, et al. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma J. Clin. Oncol., November 1, 2009; 27(31): 5213 - 5218. [Abstract] [Full Text] [PDF] S. A. Pileri and B. Falini Mantle cell lymphoma Haematologica, November 1, 2009; 94(11): 1488 - 1492. [Full Text] [PDF] M. Ghielmini and E. Zucca How I treat mantle cell lymphoma Blood, August 20, 2009; 114(8): 1469 - 1476. [Abstract] [Full Text] [PDF] P Rasmussen, L D Sjo, J U Prause, E Ralfkiaer, and S Heegaard Mantle cell lymphoma in the orbital and adnexal region Br J Ophthalmol, August 1, 2009; 93(8): 1047 - 1051. [Abstract] [Full Text] [PDF] A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting Blood, May 7, 2009; 113(19): 4604 - 4613. [Abstract] [Full Text] [PDF] C. S. Tam, R. Bassett, C. Ledesma, M. Korbling, A. Alousi, C. Hosing, P. Kebraei, R. Harrell, G. Rondon, S. A. Giralt, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood, April 30, 2009; 113(18): 4144 - 4152. [Abstract] [Full Text] [PDF] P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, et al. Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma J. Clin. Oncol., March 10, 2009; 27(8): 1209 - 1213. [Abstract] [Full Text] [PDF] A. Goy, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study Ann. Onc., March 1, 2009; 20(3): 520 - 525. [Abstract] [Full Text] [PDF] J. J. Shah, L. Fayad, and J. Romaguera Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD Blood, September 15, 2008; 112(6): 2583 - 2583. [Full Text] [PDF] O. Determann, E. Hoster, G. Ott, H. Wolfram Bernd, C. Loddenkemper, M. Leo Hansmann, T. E. F. Barth, M. Unterhalt, W. Hiddemann, M. Dreyling, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group Blood, February 15, 2008; 111(4): 2385 - 2387. [Abstract] [Full Text] [PDF] B. S. Kahl New Therapeutic Strategies for Mantle Cell Lymphoma ASCO Educational Book, January 1, 2008; 2008(1): 392 - 397. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020